MSS 4QFY21 results were operationally in-line as EBITDA grew 24% YoY to Rs17.2b (PLe Rs17.7b) with margins at 10.1% (+90bp YoY, PLe 10.7%) led by continued healthy performance in key global businesses. SMRP BV's healthy order book at Eur15.6b (with Eur4.5b new orders won in 2HFY21) will drive healthy revenues over FY22-24. Sound working capital management and controlled capex led consol net debt to decline by Rs48b in FY21 (v/s Rs69b in FY20). We expect deleveraging to continue for organic business as strong...